Will the Biotech Rebound Run into Pricing Policy Obstacles?
Feb 27, 2024•13 min•Season 2Ep. 20
Episode description
Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.
For the best experience, listen in Metacast app for iOS or Android
